Phase II Study of Revlimid (Lenalidomide), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation
Current multiple myeloma therapies, typically an induction regimen followed by consolidation
therapy with high dose chemotherapy and autologous stem cell rescue (autologous
transplantation), can induce remission but relapse and death are inevitable. A growing body
of literature suggests that consolidation therapy with autologous transplantation does not
confer additional survival benefit and may have increased procedure-related morbidity and
mortality in patients over 65 years old. Autologous transplantation is no longer
recommended as standard care for this population. In addition, certain patients may not be
eligible for autologous transplantation due to co-morbid medical conditions or may elect not
to undergo the procedure for personal reasons.
The historic standard of care for multiple myeloma patients who were not eligible for
autologous transplantation for consolidation was induction therapy with melphalan/
prednisone (MP), often followed by some form of maintenance therapy after achievement of
complete or partial remission. A recent phase 3 study showed that the addition of
thalidomide to MP (MPT) demonstrated higher overall and complete response rates. For
patients who are eligible for autologous transplantation, thalidomide/ dexamethasone (Thal
Dex) induction therapy is considered the standard of care, but a phase 2 study of
lenalidomide (Revlimid)/ dexamethasone (Rev Dex) induction therapy demonstrated higher
overall and complete response rates compared to Thal Dex. In addition, lenalidomide has a
favorable side effect profile compared to thalidomide. Based on these data, we hypothesize
that the combination of Revlimid/ melphalan/ dexamethasone (ReMeDex) induction therapy for
myeloma patients who are not planned for autologous transplantation due to age restriction
or other factors may demonstrate higher overall and/ or complete response rates with fewer
side effects.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
overall and complete response rates
every 28 days during therapy and every month after therapy for 2 years
No
Hearn J Cho, MD
Principal Investigator
New York University School of Medicine
United States: Institutional Review Board
07-919
NCT00843310
November 2008
October 2011
Name | Location |
---|---|
Bellevue Hospital | New York, New York 10016 |
NYU Cancer Center | New York, New York 10016 |
NYU Tisch Hospital | New York, New York 10016 |